Acute positive inotropic intervention phosphodiesterase inhibitors Phosphodiesterase inhibitors selective cAMP-specific cardiac vascular PDE III new group agents treatment heart failure present clinical shortterm intravenous use research intravenous amrinone milrinone FDA amrinone available general clinical use Selective phosphodiesterase inhibition beneficial actions positive inotropy peripheral vasodilation result cardiac vascular muscle concentrations intracellular cAMP ionic calcium addition positive lusitropic action enhancement cardiac relaxation beta-adrenergic agonist activity inhibition sodium-potassium ATPase agents magnitude hemodynamic improvement cardiac glycosides comparable intravenous catecholamines dobutamine different pharmacodynamic profile PDE inhibitors additive effects cardiac glycosides complementary synergistic actions catecholamines favorable effects coronary hemodynamics result continued enthusiasm short-term intravenous use amrinone milrinone setting acute heart failure systolic dysfunction myocardial infarction open heart surgery infectious toxic myocarditis heart failure right ventricular systolic dysfunction patients severe heart failure cardiac transplantation Initiation treatment intravenous bolus maintenance infusion prompt increases stroke volume cardiac output simultaneous reductions right ventricular filling pressures systemic vascular resistance 